SCI Abstract

search
+
Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells
Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells
Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (...
Obesity increases DNA damage in the breast epithelium
Obesity increases DNA damage in the breast epithelium
Obesity is a modifiable risk factor for breast cancer. Yet, how obesity contributes to cancer initiation is not fully unde...
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer r...
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural kill...
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Pathological complete response (pCR) is an established surrogate marker for prognosis in patients with breast cancer (BC) ...
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis
Breast cancer is the most common malignant tumor among women worldwide and remains one of the leading causes of death amon...
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better o...
Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study
Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study
Elevated mammographic density (MD) for a woman’s age and body mass index (BMI) is an established breast cancer risk ...
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocr...
Plasma metabolomics profiles and breast cancer risk
Plasma metabolomics profiles and breast cancer risk
Breast cancer (BC) is the most common cancer in women and incidence rates are increasing; metabolomics may be a promising ...
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated ...
An essential gene signature of breast cancer metastasis reveals targetable pathways
An essential gene signature of breast cancer metastasis reveals targetable pathways
The differential gene expression profile of metastatic versus primary breast tumors represents an avenue for discovering n...
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019
Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy pa...
Association of early menarche with breast tumor molecular features and recurrence
Association of early menarche with breast tumor molecular features and recurrence
Early menarche is an established risk factor for breast cancer but its molecular contribution to tumor biology and prognos...
TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription
TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription
Triple-negative breast cancer (TNBC) represents a highly aggressive subset of breast malignancies characterized by its cha...
Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover
Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover
The wide heterogeneity in the appearance of breast lesions and normal breast structures can confuse computerized detection...
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth
The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen ...
Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women
Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women
One major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contr...
Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case–control study
Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case–control study
There is increasing evidence that artificial intelligence (AI) breast cancer risk evaluation tools using digital mammogram...
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast ...
Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study
Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study
Based on the molecular expression of cancer cells, molecular subtypes of breast cancer have been applied to classify patie...
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and leads to the poorest patient outcome...
Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
The aim of the study was to compare the difference in survival between invasive ductal (IDC) and lobular carcinoma (ILC). ...
Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study
Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study
Women with dense breasts have an increased risk of breast cancer. However, breast density is measured with variability, wh...
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact c...
The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling
The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling
Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to re...
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathol...
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer
Window-of-opportunity (WOO) studies provide insights into the clinical activity of new drugs in breast cancer. AMEERA-4 (N...
Blocking channels to metastasis: targeting sodium transport in breast cancer
Blocking channels to metastasis: targeting sodium transport in breast cancer
The development of therapies that can suppress invasion and prevent metastasis, ‘anti-metastatic drugs’, is an...
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of ...
Load More
format_indent_increase